Roche entered into a definitive agreement to acquire Telavant Holdings, a Roivant company owned by Roivant Sciences Ltd. and Pfizer, for $7.1 billion upfront and a near-term milestone payment of $150 million. Upon closing, Roche will have full rights to further develop and manufacture RVT-3101, a novel TL1A directed antibody, and commercialize it in the U.S. and Japan.   RVT-3101 is a promising new therapy in development for inflammatory bowel disease, including ulcerative colitis and Crohn’s ...